Article PDF
Avoid common mistakes on your manuscript.
References
Keating, A. (2012). Mesenchymal stromal cells: new directions. Cell Stem Cell 10, 709–716.
Leng, Z., Zhu, R., Hou, W., Feng, Y., Yang, Y., Han, Q., Shan, G., Meng, F., Du, D., Wang, S., et al. (2020). Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 11, 216.
Middleton, E.A., He, X.Y., Denorme, F., Campbell, R.A., Ng, D., Salvatore, S.P., Mostyka, M., Baxter-Stoltzfus, A., Borczuk, A.C., Loda, M., et al. (2020). Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136, 1169–1179.
Moll, G., Ankrum, J.A., Kamhieh-Milz, J., Bieback, K., Ringdén, O., Volk, H.D., Geissler, S., and Reinke, P. (2019). Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med 25, 149–163.
Shahani, P., and Datta, I. (2021). Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much? Cytotherapy 23, 861–873.
Zhu, R., Yan, T., Feng, Y., Liu, Y., Cao, H., Peng, G., Yang, Y., Xu, Z., Liu, J., Hou, W., et al. (2021). Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms. Cell Res doi: https://doi.org/10.1038/s41422-021-00573-y.
Author information
Authors and Affiliations
Corresponding author
Additional information
Compliance and ethics
The author(s) declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Keating, A. Treatment of COVID-19 with MSCs: how does it work?. Sci. China Life Sci. 65, 849–850 (2022). https://doi.org/10.1007/s11427-021-2022-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-021-2022-5